ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth
19.5.2026 08:00:00 CEST | Business Wire | Press release
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth
Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical development.
As part of this transition, co-founder Bertrand Magy will move into the role of Chief Operating Officer, and co-founder Max Houry will assume the role of Chief Business Officer. Mr. Magy will focus on operations and the continued development of ATB’s proprietary antibody weaponization technology platform, while Mr. Houry will lead business development, strategic partnerships, and licensing activities.
This leadership transition supports ATB’s next stage of growth, with a focus on the validation of ATB’s platform and preparing for clinical development.
Mark Throsby, PhD, Chief Executive Officer of ATB Therapeutics, said: “Since the closing of our EUR 54 million Series A financing in 2024, we have made strong progress in strengthening our team, expanding our capabilities, and validating our science. I am honored to take on the role of CEO and excited to continue working closely with Bertrand, Max, the Board, and the broader ATB team as we advance our mission and bring atbodies closer to patients.”
Bertrand Magy, PhD, co-founder of ATB Therapeutics, said: “From the beginning, ATB has been driven by a shared vision to create a new class of therapies with real patient impact. It has been an extraordinary scientific and entrepreneurial journey, and I am very proud of what we have accomplished so far. I look forward to continuing to work closely with Mark, Max, and the team as we enter this next chapter.”
Max Houry, co-founder of ATB Therapeutics, said: “Over the past years, we have transformed an initial scientific concept into a promising therapeutic platform. Together with Bertrand and Mark, we have built strong foundations for the Company’s future. In my new role, I will focus on translating that momentum into strategic partnerships and business opportunities that can help bring meaningful therapies to patients.”
Mark Throsby earned his PhD in Immunology from Monash University in Melbourne, Australia, and spent four years as a research fellow at CNRS in Paris. He began his industry career at Crucell (acquired by Johnson & Johnson for USD 2.4 billion), where he spent eight years in various roles, including Director of Antibody Discovery. Prior to joining ATB, he served at Merus (acquired by Genmab for USD 8.0 billion) as COO and later CSO, where he played a key role in the development of the bispecific antibody therapeutics petosemtamab and zenocutuzumab. He is an expert in antibody engineering and immunology, with more than a dozen granted patents and > 50 peer-reviewed publications.
About ATB Therapeutics
ATB Therapeutics is an emerging biotechnology company developing atbodies, the next‑generation of weaponized antibody therapies powered by a proprietary portfolio of differentiated payloads with unique modes of action. By integrating these innovative payloads into advanced antibody formats, ATB Therapeutics aims to deliver more precise and potent treatment options for patients across oncology and autoimmune diseases. The company is building a new class of targeted therapeutics designed to overcome limitations of conventional approaches and address significant unmet medical needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260513198633/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Splio Enters a New Phase of Its Regional Development in Southern Europe19.5.2026 09:00:00 CEST | Press release
As consumers integrate AI into their everyday web usage, Splio is strengthening its presence in Barcelona to help companies across the region make CRM a central lever in the age of agentic commerce Splio is strengthening its presence in Barcelona, which is set to play the role of a second headquarters, to drive its development across Southern Europe.Splio is reinforcing governance, teams and resources deployed in the region.With its AI-first CRM, Splio aims to help companies from retail to travel strengthen the business contribution of CRM. A few months after launching its AI-first CRM, Splio is entering a new phase of its development in Southern Europe. Already established for more than 12 years in Spain, Portugal and Italy, the company has chosen to invest further in the region, convinced that it combines economic potential with rapidly evolving digital usage. Antoine Parizot, Splio’s co-CEO, is relocating to Barcelona, where the company’s historic office is based. At the same time,
KfW, Germany’s largest national promotional bank, future-proofs regulatory reporting, by migrating to Regnology Reporting Hub (RRH)19.5.2026 08:33:00 CEST | Press release
Longstanding client transitions to the next-generation RRH solution, delivered on Regnology’s Rcloud architecture Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced that KfW Bankengruppe (KfW) is advancing its long-term partnership with the company by electing to migrate to the next-generation Regulatory Reporting Hub (RRH). The solution will be delivered as a cloud-native service on Rcloud, Regnology’s high-performance cloud architecture layer. This strategic move to the modern RRH platform future-proofs the mission-critical reporting functions for one of the world's leading promotional banks. Headquartered in Frankfurt am Main, KfW is a public‑law institution dedicated to supporting sustainable economic, social and ecological development in Germany, across Europe and globally. Regnology’s foresight led to the 2023 launch of Rcloud, its state-of-the-art architecture layer built on Google Cloud, enabling next‑generation so
TREASoURcE Shows How Circular Economy Solutions Can Move Beyond Pilots Across Sectors and Regions19.5.2026 07:00:00 CEST | Press release
Across Europe, many circular economy solutions struggle to move beyond isolated pilots and into real-world deployment at scale. New approaches are needed that combine technical feasibility, market relevance and citizen engagement, while remaining adaptable to local contexts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518914041/en/ TREASoURcE addressed circular economy challenges across energy, plastics and biobased side streams, combining technical solutions with stakeholder and citizen engagement. The EU-funded TREASoURcE project provides evidence that systemic, citizen-engaged circular economy solutions can be developed, tested and prepared for replication across regions. Using a common regional approach, the project combined real-life demonstrations, cross-value chain collaboration and early consideration of transferability to translate circular economy concepts into practical solutions in the fields of energy, mat
Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer19.5.2026 07:00:00 CEST | Press release
Experienced biotech finance leader with over 30 years’ experience in capital markets and strategyProven track record in fundraising, M&A and company transformationCompany is currently running two pivotal Phase 3 studies with nizubaglustat in GM1/ GM2 gangliosidoses and Niemann-Pick type C disease Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer. Ms. Sullivan brings more than 30 years’ experience in the life sciences sector, with expertise in capital raising, corporate strategy and communications. She joins Azafaros from IO Biotech, where she served as Chief Financial Officer. “Amy is a highly accomplished financial leader with a strong track record of supporting growth-stage biotech companies,” said Stefano Portolano, Chief Executive Officer at Azafaros. “Her expertise in financing, strategic positioning a
Shufti Recognised as Dual Leader in Liminal's 2026 Age Verification and Age Estimation Indexes, with Exceptional Ratings Across Both Benchmarks19.5.2026 07:00:00 CEST | Press release
Liminal’s independent buyer-led research positions Shufti among the highest-scoring vendors on Product Execution, Strategy, and Market Presence, citing its risk-based age assurance, sub-second inference, and privacy-preserving on-device capabilities. Shufti has been named a Leader in both the Age Verification and Age Estimation categories of Liminal’s 2026 Index Report, receiving an Exceptional rating for Market Presence across both. Liminal, an actionable intelligence firm, evaluates identity verification vendors across Product Execution, Strategy, and Market Presence, assessing scalability, accuracy, fraud resistance, innovation, and user experience. Out of 189 vendors assessed in the Age Verification Index, only 17 achieved Leader status. Shufti was among them and exceeded the leadership threshold with a 64% Product Execution score and a 92% Strategy score. In Age Estimation, Shufti again ranked among 17 Leaders from 80 evaluated vendors, exceeding leadership thresholds across core
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom